Latest Options News

Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.

Australia’s ANSTO has independently confirmed that Lindian Resources’ Kangankunde monazite concentrate is exempt from radioactive transport classification, simplifying export logistics and lowering downstream costs.

Sky Network Television posts a robust first half FY26 with 8% revenue growth and a 77% rise in underlying net profit, driven by the strategic acquisition and integration of Discovery NZ, now Sky Free.

Aurora Energy Metals has completed the sale of its Aurora Uranium Project to Eagle Nuclear Energy, receiving A$24.2 million in equity and retaining future milestone-linked payments and royalties.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Sprintex Limited reported a 162% surge in revenue to A$2.7 million for the half-year ending December 2025, driven by a landmark €15.6 million European contract. Despite this, the company posted a net loss of A$1.7 million, an improvement from the prior year, while raising $3.6 million to support global expansion.

Suncorp Group Limited has updated its dividend distribution details, confirming a fully franked ordinary dividend of AUD 0.17 per share payable in March 2026, with tailored currency payment options for shareholders.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Acorn Capital Investment Fund Limited has reported a remarkable half-year performance for the period ending 31 December 2025, with revenue and profit soaring over 300%. The fund also declared a fully franked interim dividend of 3.5 cents per share, signalling confidence in its investment strategy.

MA Credit Income Trust reported a strong half-year profit of $19.7 million, exceeding its return target, while successfully completing a $190.5 million capital raise and initiating a strategic buy-back to manage liquidity.